Fox Business - The Power to Prosper
Search Site

AstraZeneca

Drugmakers under fire over off-label marketing

FBN’s Liz MacDonald says Public Citizen is urging the FDA to pull ads for five type-2 diabetes drugs over unapproved claims and off-label marketing.

Read More

  1. Global M&A deal adds up to $1.75T

    Mesirow Financial Vice Chairman Jeff Golman on major M&A deals and tips on investing.

  2. Conard: Unpatriotic tax policies are damaging our economy

    Former Bain Capital managing director Ed Conard and The Vanguard Group CEO Bill McNabb on businesses parking cash overseas.

  3. Is the profit picture peaking?

    FOX Business contributor Jon Hilsenrath and Macromavens founder Stephanie Pomboy on American companies going overseas.

  4. 22% corporate tax instead of 35%?

    FBN’s Liz MacDonald on the potential of lowering corporate tax rates to stimulate the economy.

  5. France to buy 20% stake in Alstom, clearing way for GE deal

    Alpari’s Josh Mahony on the European markets brief.

  6. Eli Lilly CEO talks M&A

    Eli Lilly CEO John Lechleiter argues the company doesn’t need to make bid deals to grow.

  7. When will an Alstom takeover deal be signed?

    Alpari’s James Hughes on the European markets.

  8. The tax motivations of Medtronics’ Covidien deal

    U.S. Congressional candidate Claudia Tenney and Swiss America Trading Chairman Craig Smith on businesses’ efforts to reduce their tax burden.

  9. Medtronic buying Covidien for $42.9B

    Dana Mattioli of The Wall Street Journal, Reason Magazine editor-in-chief Matt Welch and Jones Trading chief market strategist Michael O’Rourke on companies leaving the U.S. to get lower tax rates.

  10. Europe regulators target Apple tax probe

    FOX Business contributor Bob Rice breaks down why Apple is facing questions by European regulators over taxes.

  11. Putting money to work in Europe and Japan

    FTN Financial chief economist Chris Low and Gerber Kawasaki CEO Ross Gerber discuss the European and Japanese economies.

  12. The key to stock-picking perfection

    M.D. Sass CEO Martin D. Sass gives insight into the markets.

  1. The latest drugs being tested to fight melanoma

    Array BioPharma CEO Ron Squarer on the latest treatments tested in the pharmaceutical industry to battle cancer.

  2. Treasury takes aim at corporate inversion

    FBN’s Liz MacDonald on deal stocks under pressure as the U.S. announces stricter tax rules.

  3. Lilly CEO sees margins hitting pre-patent cliff levels by ‘19

    Eli Lilly CEO John Lechleiter discusses 2Q earnings and the impact of recent patent expirations.

  4. Johnson & Johnson CEO: We are staying in the U.S.

    Johnson & Johnson CEO Alex Gorsky discusses companies moving business out of the U.S. because of taxes and ObamaCare’s impact.

  5. What is behind the success of specialty pharma?

    Sanford Bernstein analyst Ronny Gal on the business model of specialty pharma.

  6. What is behind the success of specialty pharma?

    Sanford Bernstein analyst Ronny Gal on the business model of specialty pharma.

  7. Mega-deals to ramp up in August?

    Rich Jeanneret of E&Y Transaction Adivsor Americas, Jones Day Global M&A chairman Bob Profusek and Hedgeye Risk Management CEO Keith McCullough give their outlook for M&A deals.

‹ Prev12345Next ›
Freebase CC-BY
Source: AstraZeneca on Freebase, licensed under CC-BY
Other content from Wikipedia, licensed under the GFDL